Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ).
Shandong Xinhua Pharmaceutical has obtained National Medical Products Administration approval for its BUMETANIDE Injection, a prescription diuretic product in 2ml:0.5mg and 4ml:1mg specifications, classed as a Class 3 chemical drug for domestic production. The issuance of the drug registration certificate allows the company to commence compliant manufacturing and sales once GMP and other quality standards are met, strengthening its injectable portfolio and potentially enhancing its competitive position in China’s hospital pharmaceutical market.
The product’s approval confirms that its quality standards, labeling, instructions and production processes satisfy current Chinese drug regulatory requirements. This regulatory milestone may support Xinhua Pharmaceutical’s broader strategy to expand its presence in regulated prescription markets and deepen its relationships with institutional healthcare buyers.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer listed in Hong Kong and the mainland, focused on developing, producing and selling chemical drugs. The company supplies prescription medicines to the domestic market, targeting hospital and clinical demand across multiple therapeutic areas.
Average Trading Volume: 969,040
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.65B
See more data about 0719 stock on TipRanks’ Stock Analysis page.